Drug intelligence / Profile preview

AVTN30X

Development stage: Preclinical
Lead developer: Aventi Biotechnology
Modality: Small Molecules

Overview

AVTN30X is a small molecule drug candidate currently in preclinical development by Aventi Biotechnology. It is being investigated for the treatment of muscle-wasting conditions, specifically sarcopenia (age-related muscle loss) and cachexia (muscle wasting associated with chronic illnesses). As of the current pipeline information, the specific molecular target and mechanism of action for AVTN30X have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on AVTN30X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVTN30X.

Explore the full profile